Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06185166
Other study ID # 8780
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 5, 2022
Est. completion date June 5, 2024

Study information

Verified date December 2023
Source University Hospital, Strasbourg, France
Contact Loïc KASSEGNE, MD
Phone 33 3 69 55 01 88
Email loic.kassegne@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Non-tuberculous mycobacteriosis (NTM) are infectious diseases caused by mycobacteria that are not part of the Tuberculosis complex. More than 190 species have been identified to date. As an environmental reservoir, it most often affects the lungs, skin and soft tissues, lymph nodes, but it can affect all organs. Varying in virulence depending on the species, most infections do not cause illness. There is currently no coordinated care pathway for this pathology in Alsace. The means necessary to set up such a structure requires knowing the importance of the disease.


Description:

The aim of the study is to determine the incidence of non-tuberculous mycobacterial infections in the ALSACE region, the proportion of cases in which the infection causes illness, and its evolution over time.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 5, 2024
Est. primary completion date June 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult subject (= 18 years old) - in whom a biological sample is culture positive for a non-tuberculous mycobacterium - born in France and domiciled in Alsace (i.e. whose home postal code begins with 67 or 68) - not opposing the reuse of its data for scientific research purposes Exclusion Criteria: - Subject having expressed opposition to participating in the study - not domiciled in Alsace - Born abroad - Isolation of a mycobacterium from the Tuberculosis complex and Mycobacterium gordonae

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Service de Pneumologie - CHU de Strasbourg - France Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retrospective description of non-tuberculous mycobacteria in Alsace Through study completion, an average of 6 months
See also
  Status Clinical Trial Phase
Completed NCT04884308 - Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections Phase 2